SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: epicure who wrote (1103)5/27/1998 7:00:00 PM
From: Nero  Read Replies (1) | Respond to of 2135
 
Monkey trials for endostatin this summer. Output increasing to 500 liters. I like the timetable.

ENMD cash-raising options:
1) Partner for endostatin infusing cash.
2) Increasing outstanding shares from current float of about 12 million.
3) Reinforcing investment banking relationships -- whatever that means.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News